+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
ONESOURCE

OneSource Specialty Pharma Share Price

₹1,581.70 -36.3 (-2.24%)
49.64% Gain from 52W Low

11 Nov, 2026 3:59 PM (IST)

OneSource Specialty Pharma live price: ₹1,581.70. It opened at ₹1,621 vs previous close ₹1,618; intraday high/low: ₹1,644/₹1,577. The 50 & 200 DMA stand at ₹1,539.70/₹1,586.30.

OneSource Specialty Pharma Performance

  • Today's Low
  • ₹1,577
  • Today's High
  • ₹1,644
  • 52 Week Low
  • ₹1,057
  • 52 Week High
  • ₹1,918
  • Open Price₹1,621
  • Previous Close₹1,618
  • Volume229,817
  • 50 DMA₹1,539.70
  • 100 DMA₹1,560.30
  • 200 DMA₹1,586.30

OneSource Specialty Pharma Chart

Investment Returns

  • Over 1 Month + 8.24%
  • Over 3 Month + 0.4%
  • Over 6 Month -13.81%
  • Over 1 Year -11.71%

Smart Investing Starts Here Start SIP with OneSource Specialty Pharma for Steady Growth!

Invest Now

OneSource Specialty Pharma Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -11189.2
  • PEG Ratio
  • 107.5
  • Market Cap Cr
  • 18,138
  • P/B Ratio
  • 3.1
  • Average True Range
  • 59.5
  • EPS
  • -0.1
  • Dividend Yield
  • 0
  • MACD Signal
  • 28.7
  • RSI
  • 56.39
  • MFI
  • 80.12

Latest Stock News Updates

Onesource Specialty Pharma Ltd - 544292 - The Company Is Informing The Exchange About Participation In Jefferies Global Healthcare Conference.

Onesource Specialty Pharma Limited has informed the Exchange about the Participation in Jefferies Global Healthcare Conference to be held from November 16, 2026 to November 19, 2026 in London.

Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

Intimation of Transcript of Earnings call dated October 27, 2026

Onesource Specialty Pharma Ltd - 544292 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

OneSource receives USFDA EIR with VAI Classification, Marking completion of Inspection process at its Sterile Product Division (SPD) Facility in Bengaluru.

OneSource Specialty Pharma Financials

OneSource Specialty Pharma Technicals

EMA & SMA

Current Price
₹1,581.70
-36.3 (-2.24%)
pointer
  • Bearish Moving Average 5
  • Bullish Moving Average 11
  • 20 Day
  • ₹1,546.90
  • 50 Day
  • ₹1,539.70
  • 100 Day
  • ₹1,560.30
  • 200 Day
  • ₹1,586.30

Resistance and Support

1600.73 Pivot Speed
  • R3 1,692.50
  • R2 1,668.20
  • R1 1,625.00
  • S1 1,557.50
  • S2 1,533.20
  • S3 1,490.00

OneSource Specialty Pharma Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-10-27 Quarterly Results
2026-07-24 Quarterly Results
2026-05-13 Audited Results
2026-01-23 Quarterly Results
2025-11-11 Quarterly Results

OneSource Specialty Pharma Shareholding Pattern

30.47%
25.86%
19.45%
13.76%
10.44%

About OneSource Specialty Pharma

OneSource Specialty Pharma focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). View More
  • NSE Symbol
  • ONESOURCE
  • BSE Symbol
  • 544292
  • Executive Director,Managing Director,Chief Executive Officer
  • Neeraj Sharma
  • ISIN
  • INE013P01021

Similar Stocks to OneSource Specialty Pharma

OneSource Specialty Pharma FAQs

OneSource Specialty Pharma share price is ₹1,581 As on 11 November, 2026 | 19:26

The Market Cap of OneSource Specialty Pharma is ₹18138 Cr As on 11 November, 2026 | 19:26

The P/E ratio of OneSource Specialty Pharma is -11189.2 As on 11 November, 2026 | 19:26

The PB ratio of OneSource Specialty Pharma is 3.1 As on 11 November, 2026 | 19:26

The 52 week High & Low of OneSource Specialty Pharma is ₹1917.8/₹1057 respectively As on 11 November, 2026 | 19:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23